Results 21 to 30 of about 19,263 (243)

New Methods in Treatment of Renal failure in Patients with Multiple Myeloma: A Review with Immunological Approach. [PDF]

, 2017
Multiple myeloma (MM), as one of a variety of autoimmune diseases, affects the immune system and, on the other hand, is considered to be a hematologic impairment.
Iranparast, Sara., Saeedi-Boroujeni, Ali., Shirani, Majid.   +2 more
core   +1 more source

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Blood Advances, 2017
: Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma.
Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser   +13 more
doaj   +1 more source

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Haematologica, 2020
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple
Anna Vidal-Crespo, Alba Matas-Céspedes, Vanina Rodriguez, Cédric Rossi, Juan G. Valero, Neus Serrat, Alejandra Sanjuan-Pla, Pablo Menéndez, Gaël Roué, Armando López-Guillermo, Eva Giné, Elías Campo, Dolors Colomer, Christine Bezombes, Jeroen Lammerts van Bueren, Christopher Chiu, Parul Doshi, Patricia Pérez-Galán   +17 more
doaj   +1 more source

Bone marrow senescence and the microenvironment of hematological malignancies [PDF]

, 2020
Senescence is the irreversible arrest of cell proliferation that has now been shown to play an important role in both health and disease. With increasing age senescent cells accumulate throughout the body, including the bone marrow and this has been ...
Bowles, Kristian M., Hellmich, Charlotte, Moore, Jamie A., Rushworth, Stuart A.   +3 more
core   +1 more source

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells.
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon   +17 more
doaj   +1 more source

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

Therapeutics and Clinical Risk Management, 2023
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Hughes MS, Lentzsch S
doaj  

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Hematology, Transfusion and Cell Therapy, 2021
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM).
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot   +7 more
doaj   +1 more source

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party [PDF]

, 2017
Non peer ...
Beguin, Yves, Chevalier, Patrice, Dubois, Valerie, El-Cheikh, Jean, Fegueux, Nathalie, Finke, Juergen, Francois, Sylvie, Garban, Frederic, Garderet, Laurent, Gluckman, Eliane, Iacobelli, Simona, Koster, Linda, Kroeger, Nicolaus, Lioure, Bruno, Maertens, Johan, Maillard, Natacha, Meijer, Ellen, Michallet, Mauricette, Passweg, Jakob, Petersen, Eefke, Ruggeri, Annalisa, Russell, Nigel, Schipperus, Martin, Sobh, Mohamad, Tabrizi, Reza, Tholouli, Eleni, Van Biezen, Anja, Volin, Liisa, von dem Borne, Peter   +28 more
core   +3 more sources

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma [PDF]

, 2016
Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with ...
Abidi, Alexanian, Attal, Attal, Attal, Attal, Attal, Badros, Baldini, Ballestrero, Barlogie, Barlogie, Barlogie, Barlogie, Barlogie, Bartel, Beaven, Berdeja, Berenson, Bernard Maybury, Bladé, Blanes, Cancer Research UK, Cavo, Cavo, Chauhan, Chen, Child, Chérel, Comenzo, Desikan, Dimopoulos, Dispenzieri, Dispenzieri, Donato, Drayson, Durie, Fenk, Fermand, Fermand, Forsberg, Garfall, Garg, Gay, Giralt, Goel, Gordon Cook, Govindarajan, Green, Guy Pratt, Harousseau, Harousseau, Huang, Jakubowiak, Karthik Ramasamy, Kazmi, Kelly, Knop, Kochenderfer, Kumar, Kwee Yong, Lacy, Ladetto, Lahuerta, Lahuerta, Lebovic, Leleu, Lokhorst, Lokhorst, Lonial, Lonial, Ma, Magarotto, Mai, Maiolino, Marin, Mark, Maude, McCann, McCarthy, Mellqvist, Mihara, Mitsiades, Miyamoto, Moreau, Moreau, Moreau, Morgan, Nair, Nath, Nishihori, Nooka, Orchard, Paiva, Palumbo, Palumbo, Pica, Pineda-Roman, Plesner, Popat, Pulte, Qazilbash, Rabin, Rapoport, Rapoport, Rawstron, Riccardi, Rosenblatt, Roussel, Roussel, Rueff, San Miguel, San-Miguel, Sborov, Scheid, Shi, Sonneveld, Sonneveld, Sonneveld, Sonneveld, Spencer, Spencer, Stewart, Stewart, Tacchetti, Voorhees, Zahradova, Zamagni, Zimmerman   +128 more
core   +2 more sources

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma [PDF]

, 2021
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo.
Bos, Gerard M.J., Broijl, Annemiek, Frerichs, Kristine A., Kersten, Marie Jose, Klein, Saskia K., Levin, Mark David, Maas-Bosman, Patricia W.C., Minnema, Monique C., Mutis, Tuna, Nijhof, Inger S., Sonneveld, Pieter, Van de Donk, Niels W.C.J., Verkleij, Christie P.M., Zweegman, Sonja   +13 more
core   +4 more sources